- South Korea
- /
- Pharma
- /
- KOSDAQ:A084110
Insiders were the key beneficiaries as Huons Global Co., Ltd.'s (KOSDAQ:084110) market cap rises to ₩461b
Key Insights
- Insiders appear to have a vested interest in Huons Global's growth, as seen by their sizeable ownership
- The largest shareholder of the company is Sung-Tae Yoon with a 54% stake
- Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
A look at the shareholders of Huons Global Co., Ltd. (KOSDAQ:084110) can tell us which group is most powerful. We can see that individual insiders own the lion's share in the company with 59% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, insiders were the biggest beneficiaries of last week’s 10% gain.
In the chart below, we zoom in on the different ownership groups of Huons Global.
See our latest analysis for Huons Global
What Does The Institutional Ownership Tell Us About Huons Global?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Institutions have a very small stake in Huons Global. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. So if the company itself can improve over time, we may well see more institutional buyers in the future. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
Huons Global is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Sung-Tae Yoon with 54% of shares outstanding. With such a huge stake in the ownership, we infer that they have significant control of the future of the company. With 4.3% and 1.7% of the shares outstanding respectively, Insang Yun and The Vanguard Group, Inc. are the second and third largest shareholders.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Huons Global
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own the majority of Huons Global Co., Ltd.. This means they can collectively make decisions for the company. Given it has a market cap of ₩461b, that means they have ₩271b worth of shares. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling.
General Public Ownership
With a 37% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Huons Global. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Huons Global better, we need to consider many other factors. For example, we've discovered 3 warning signs for Huons Global (1 is potentially serious!) that you should be aware of before investing here.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Valuation is complex, but we're here to simplify it.
Discover if Huons Global might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A084110
Huons Global
Manufactures and sells pharmaceutical products for human health in South Korea and internationally.
Excellent balance sheet low.
Market Insights
Community Narratives
![ChadWisperer](https://lh3.googleusercontent.com/-XdUIqdMkCWA/AAAAAAAAAAI/AAAAAAAAAAA/4252rscbv5M/photo.jpg)